Reading TCRT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRT free→Reading TCRT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRT free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, while management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is high, and the sector backdrop is a headwind, with performance below typical for sector peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $2.24. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.24, TCRT's earnings are too small for P/E to mean much; on sales it trades at 359× p/s (37.2× the 10× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $0.31 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 779% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.76x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
17 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$200.
How much price usually moves either way.
On a bad day, this stock has moved -$872.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,550.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Composite insight fell by 13.8 points (from -12.2 to -26.0).
Valuation label changed from 'None' to 'expensive'.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TCRT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TCRT ALAUNOS THERAPEUTICS INC | Below typical Show detailsSector percentile: 3 of 100 | expensive | high |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Address the Nasdaq listing rule compliance issue to maintain stock listing.
Newly stated in 2026-Q1. The company received a notice from Nasdaq for non-compliance with Listing Rule 5550(b)(1), which requires maintaining a minimum of $2,500,000 in stockholders' equity. The company must address this issue to maintain its stock listing. Persistent statement, limited substantive delivery this quarter.
“Received a notice from Nasdaq for non-compliance with Listing Rule 5550(b)(1).”
Settle outstanding disputes with MD Anderson Cancer Center related to unpaid invoices.
Newly stated in 2025-Q4. The company entered into a Settlement Agreement with MD Anderson Cancer Center to resolve disputes related to unpaid invoices, agreeing to pay $285,055. This action addresses the financial obligation but does not reflect broader financial improvement. Persistent statement, limited substantive delivery this quarter.
“Entered into a Settlement Agreement with MD Anderson to resolve disputes.”
Engage with stockholders for potential strategic partnerships and board discussions.
Newly stated in 2025-Q4. A group of stockholders filed Schedule 13D, indicating beneficial ownership of 8.6% and intent to engage with the Board for strategic discussions. This reflects a potential for strategic partnerships but lacks immediate financial impact. Persistent statement, limited substantive delivery this quarter.
“Stockholders filed Schedule 13D to engage with the Board for strategic discussions.”
Other Events. Shareholder Nomination of Potential Board Member The Company notes the following developments regarding a group of stockholders (the “Group”) that has filed Schedules 13D with the Securities and Exchange Commission: ▪ On October 30, 2025, the Group filed an initial Schedule 13D reporting beneficial ownership of approximately 8.6% of the Company’s outstanding common stock. The filing stated the Group’s intention to engage with the Board of Directors to discuss potential ways to e…
Termination of a Material Definitive Agreement. On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effective immediately, the engagement letter dated August 14, 2023 (the “Engagement Letter”), pursuant to which Cantor had been engaged as the Company’s exclusive financial advisor in connection with the exploration of potential strategic transactions. The Engagement Letter provided that it could be terminated by the Company on or after th…
Material Modification to Rights of Security Holders. On January 8, 2026, the Board of Directors of the Company approved and adopted Amended and Restated By-Laws of the Company (the “Amended and Restated Bylaws”), effective immediately. The Amended and Restated Bylaws include, among other changes: ▪ A new Article 2, Section 2.14 establishing comprehensive procedures and requirements for stockholder nominations of director candidates and proposals of other business to be brought before annual a…
Entry into a Material Definitive Agreement On December 17, 2025, Alaunos Therapeutics, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) resolving all disputes related to unpaid invoices under the 2019 Research and Development Agreement. Under the Settlement Agreement, the Company agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices…